About METABULIN, INC
Metabulin is a biotechnology company focused on developing ultra-stable monomeric insulin to improve diabetes treatment through faster and more predictable insulin action. Their innovation addresses the stability-activity trade-off in conventional insulin by engineering insulin to remain active in its monomeric form.
Development of ultra-stable monomeric insulinBreaking the stability-activity trade-off in insulinImproving post-meal glucose control and dose-to-dose consistencyStructural biology research and protein engineering
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to METABULIN, INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.